TY - JOUR
T1 - Worldwide perspectives on venom allergy
AU - Korošec, Peter
AU - Jakob, Thilo
AU - Harb, Harfi
AU - Heddle, Robert
AU - Karabus, Sarah
AU - de Lima Zollner, Ricardo
AU - Selb, Julij
AU - Yu-Hor Thong, Bernard
AU - Zaitoun, Fares
AU - Golden, David B.K.
AU - Levin, Michael
N1 - Funding Information:
The authors acknowledge the support and review of the board of directors of the World Allergy Organization.
Publisher Copyright:
© 2019 The Authors
PY - 2019/10
Y1 - 2019/10
N2 - Venom immunotherapy is the standard of care for people with severe reactions and has been proven to reduce risk of future anaphylactic events. There is a moral imperative to ensure production, supply and worldwide availability of locally relevant, registered, standardized commercial venom extracts for diagnosis and treatment. Insects causing severe immediate allergic reactions vary by region worldwide. The most common culprits include honeybees (Apis mellifera), social wasps including yellow jackets (Vespula and Dolichovespula), paper wasps (Polistes) and hornets (Vespa), stinging ants (Solenopsis, Myrmecia, Pachycondyla, and Pogonomyrmex), and bumblebees (Bombus). Insects with importance in specific areas of the world include the Australian tick (Ixodes holocyclus), the kissing bug (Triatoma spp), horseflies (Tabanus spp), and mosquitoes (Aedes, Culex, Anopheles). Reliable access to high quality venom immunotherapy to locally relevant allergens is not available throughout the world. Many current commercially available therapeutic vaccines have deficiencies, are not suitable for, or are unavailable in vast areas of the globe. New products are required to replace products that are unstandardized or inadequate, particularly whole-body extract products. New products are required for insects in which no current treatment options exist. Venom immunotherapy should be promoted throughout the world and the provision thereof be supported by health authorities, regulatory authorities and all sectors of the health care service.
AB - Venom immunotherapy is the standard of care for people with severe reactions and has been proven to reduce risk of future anaphylactic events. There is a moral imperative to ensure production, supply and worldwide availability of locally relevant, registered, standardized commercial venom extracts for diagnosis and treatment. Insects causing severe immediate allergic reactions vary by region worldwide. The most common culprits include honeybees (Apis mellifera), social wasps including yellow jackets (Vespula and Dolichovespula), paper wasps (Polistes) and hornets (Vespa), stinging ants (Solenopsis, Myrmecia, Pachycondyla, and Pogonomyrmex), and bumblebees (Bombus). Insects with importance in specific areas of the world include the Australian tick (Ixodes holocyclus), the kissing bug (Triatoma spp), horseflies (Tabanus spp), and mosquitoes (Aedes, Culex, Anopheles). Reliable access to high quality venom immunotherapy to locally relevant allergens is not available throughout the world. Many current commercially available therapeutic vaccines have deficiencies, are not suitable for, or are unavailable in vast areas of the globe. New products are required to replace products that are unstandardized or inadequate, particularly whole-body extract products. New products are required for insects in which no current treatment options exist. Venom immunotherapy should be promoted throughout the world and the provision thereof be supported by health authorities, regulatory authorities and all sectors of the health care service.
KW - Immunotherapy
KW - Insects
KW - Venom
KW - Venom immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85073936941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073936941&partnerID=8YFLogxK
U2 - 10.1016/j.waojou.2019.100067
DO - 10.1016/j.waojou.2019.100067
M3 - Article
C2 - 31700565
AN - SCOPUS:85073936941
SN - 1939-4551
VL - 12
JO - World Allergy Organization Journal
JF - World Allergy Organization Journal
IS - 10
M1 - 100067
ER -